1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Defining the index lesion for salvage partial gland ablation after radiation therapy for localized prostate cancer
    Meeting Abstract

    Sivaraman, A.; Takaeda, T.; Vargas, H. A.; Fine, S.; Eastham, J. A.; Ehdaie, B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D)
    Meeting Abstract

    Schuler, M. H.; Ascierto, P. A.; De Vos, F. Y. F. L.; Postow, M. A.; Van Herpen, C. M. L.; Carlin, M. S.; Sosman, J. A.; Berking, C.; Long, G. V.; Weise, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells
    Meeting Abstract

    Santomasso, B.; Park, J. H.; Riviere, I.; Mead, E.; Halton, E.; Diamonte, C.; Purdon, T.; Senechal, B.; Li, D.; Sadelain, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients
    Meeting Abstract

    Sanborn, R. E.; Pishvaian, M. J.; Kluger, H. M.; Callahan, M. K.; Weise, A. M.; Lutzky, J.; Yellin, M. J.; Rawls, T.; Vitale, L.; Halim, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Combination of dabrafenib (DAB)
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Baxi, S. S.; Dunn, L.; Korte, S. H.; Haque, S.; Ghossein, R. A.; Chen, H. X.; Pfister, D. G.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical and immunologic variables associated with outcomes following combination ipilimumab and nivolumab immunotherapy in melanoma
    Meeting Abstract

    Rosner, S.; Kwong, E.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Survivor feedback on a late effects-oriented survivorship care plan for head and neck cancer
    Meeting Abstract

    Salz, T.; McCabe, M. S.; Oeffinger, K. C.; Schnall, R. B.; Corcoran, S.; Vickers, A. J.; Salner, A. L.; Dornelas, E. A.; Raghunathan, N. J.; Fortier, E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
    Meeting Abstract

    Ruppert, A. S.; Byrd, J. C.; Heerema, N. A.; Smith, M. R.; Godwin, J. E.; Couban, S.; Fehniger, T. A.; Thirman, M.; Halvorson, A. E.; Tallman, M. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save